Data from the MARINER study showed that rivaroxaban 10 mg once daily did not significantly reduce the composite of symptomatic venous thromboembolism (VTE) and VTE-related death post hospital discharge.- Bayer AG + Janssen Research & Development, LLC.
Bayer AG and its development partner Janssen Research & Development, LLC announced new data from an investigational study for its Factor Xa inhibitor rivaroxaban (Xarelto) at ESC Congress 2018, 25-29 August in Munich, Germany.
Data from the MARINER study showed that, compared to placebo, rivaroxaban 10 mg once daily did not significantly reduce the composite of symptomatic venous thromboembolism (VTE) and VTE-related death post hospital discharge in high-risk acutely medically ill patients. The major bleeding rate with rivaroxaban was generally low, and not significantly different compared to placebo.
Comment: J&J said it will still pursue a filing with U.S. regulators for Xarelto in preventing blood clots among acute medically ill patients following a hospital discharge, relying on a previous data set as well as MARINER.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins